2026 Medicare Skin Substitute Changes: What Your Wound Care Practice Needs to Do Now | Medipyxis

What Changed on January 1, 2026

If you run a wound care practice that uses advanced skin substitutes, January 1 changed your economics overnight. Here's what CMS did:

Reclassified skin substitutes as "incident-to" supplies. Cellular and tissue-based products (CTPs) are no longer reimbursed at product-specific ASP rates. They're now classified as supplies incident to a physician service under the Medicare Physician Fee Schedule.

Flat reimbursement at ~$127.14 per cm². Instead of per-product pricing that often exceeded $300–$500/cm² for premium grafts, every CTP application now reimburses at roughly the same rate. If your practice relied on high-ASP products to drive margin, that margin just collapsed.

158 products dropped from coverage. CMS narrowed the approved product list dramatically. Only about 18 skin substitute products remain eligible for Medicare coverage. Products that were generating significant revenue for many practices — including several popular fish skin, amniotic, and synthetic grafts — are no longer covered.

LCDs withdrawn — but payment policy remains. Most Medicare Administrative Contractors withdrew their Local Coverage Determinations for skin substitutes. This sounds like deregulation, but it's not. The underlying payment policy and medical necessity requirements are still in full effect. You still need to document everything. You just lost the explicit LCD roadmap that told you exactly what to document.

New prior authorization in some jurisdictions. CMS introduced the WISeR (Wound Integrity and Service Evaluation Report) model, which adds structured prior authorization requirements before skin substitute application in select regions.

This is the biggest payment policy change to hit wound care in a decade. And most practices found out about it after it was already in effect.

The Products Still Covered

The approved list is much shorter now. Roughly 18 products remain eligible for Medicare reimbursement under the new framework. The exact list varies slightly by MAC jurisdiction.

What you need to know:

Check your MAC-specific approved product list. What's covered in Palmetto GBA's jurisdiction may differ from Novitas or CGS.
FDA clearance does NOT equal Medicare coverage. A product can be FDA-cleared and still not be on the CMS-approved list.
Products dropped from coverage cannot be billed to Medicare — even if you have inventory on hand. Using a non-covered product means either the patient pays out of pocket or you absorb the cost.
The approved list can change. CMS has signaled ongoing review of which products qualify. Monitor updates quarterly at minimum.

Action step: Pull your current graft inventory today. Cross-reference every product against the MAC-approved list for your jurisdiction. If you're holding product that's no longer covered, you need a plan — now.

How This Hits Mobile Wound Care Practices

Hospital-based wound centers absorb reimbursement changes across a larger revenue base. For mobile wound care practices — especially smaller and mid-size operations — the impact is disproportionate.

Margin compression is immediate

If your average graft cost was $200/cm² and you were being reimbursed at $350–$500/cm², you had healthy margin. At $127.14/cm², the math doesn't work for many products. Practices that built their revenue model around high-ASP skin substitutes are facing a fundamental business model problem.

Documentation burden increased

Without explicit LCDs, you might think documentation requirements relaxed. They didn't. Medicare still requires proof of medical necessity, and auditors are still looking for:

4+ weeks of conservative care documented before any advanced therapy
Wound measurements (length, width, depth) at every visit with dated photographs
Vascular assessments for lower extremity wounds
Explicit medical necessity language in every note — not implied, stated

The difference is that you no longer have an LCD checklist telling you exactly what to include. You're flying without the guardrails.

Audit exposure is higher than ever

Skin substitutes remain one of the most audited categories in Medicare. CMS spent over $10 billion on wound care products in recent years, and that spending triggered scrutiny. RAC audits, MAC reviews, CERT audits, and Targeted Probe and Educate (TPE) reviews are all actively targeting wound care practices.

A denied claim isn't just lost revenue — it's a retroactive recoupment risk. Medicare can claw back payments on claims submitted years ago if documentation doesn't hold up.

Inventory write-off risk

If you're holding graft products that fell off the approved list, you have dead inventory. Products with short shelf lives compound the problem. Every day that inventory sits unused is money evaporating.

5 Steps to Protect Your Practice Now

1. Audit your product inventory against the approved list

Pull every graft product you currently stock. Check each one against your MAC's approved product list. If a product isn't on the list, stop ordering it and develop a plan for existing stock (patient self-pay, return to vendor, or write-off).

2. Recalculate your margins at $127.14/cm²

Run the math on every product you use. What does it actually cost you per cm²? What's your new margin at the flat reimbursement rate? Some products will still be profitable. Others won't be close. You need to know which is which before you apply another graft.

3. Tighten documentation before every application

Treat every graft application like it will be audited — because it might be. Before applying any skin substitute:

Confirm 4+ weeks of conservative care is documented in the chart
Verify wound measurements and photos are current (within 7 days)
Check vascular status documentation for lower extremity wounds
Write explicit medical necessity language — "Standard care failed to yield significant improvement" is the kind of phrasing Medicare looks for
Verify the product is on the approved list for your MAC jurisdiction

4. Implement a pre-application verification workflow

Don't rely on individual clinicians to remember all the steps. Build a systematic workflow:

Product approval status — is this CTP still covered?
Patient eligibility — is this patient on Medicare? Part A or Part B?
LCD/coverage criteria — does the wound meet medical necessity?
Conservative care documentation — is 4+ weeks documented?

If any of these checks fail, the application should not proceed until the gap is resolved.

5. Set up audit-ready traceability

Every graft application needs a complete chain of documentation:

Product name, lot number, and expiry date
Exact size applied (in cm²)
Waste documentation — how much was used vs. discarded, and why
HCPCS code alignment — does the code match the product and the size?
Patient-linked records — who received it, when, on which wound, by which clinician

If an auditor asks for this information 18 months from now, you need to produce it in hours — not weeks.

What This Means for Your Documentation Workflow

The practices that survive this transition will be the ones that make documentation airtight before the claim goes out — not after a denial.

Every graft application now needs:

Conservative care log (4+ weeks of standard therapies documented with dates)
Wound assessment with measurements and dated photographs
Vascular assessment results (for lower extremity wounds)
Explicit medical necessity statement using Medicare-specific language
Product verification against the approved CTP list
Lot number, size, and waste justification
Pre- and post-application wound status

The old way: Document the visit, hope billing catches any gaps, deal with denials reactively.

The new reality: If the documentation isn't complete before the clinician signs the note, the claim is at risk. Period.

How Medipyxis Handles This

We built Medipyxis with LCD compliance baked into the documentation workflow — not bolted on after the fact. Here's how it addresses the 2026 changes specifically:

LCD Navigator audits every note against Medicare coverage criteria before attestation. If conservative care documentation is missing, if wound measurements are incomplete, or if medical necessity language isn't explicit — the system flags it before the note is signed. Not after billing rejects it.

Graft Inventory ERP tracks every product by lot number, expiry date, size, and patient linkage. When a clinician applies a graft, the system captures product details at the point of care and generates audit-ready traceability logs automatically. No spreadsheets. No manual reconciliation.

Pre-application verification checks product approval status and patient eligibility as part of the visit workflow. If a product isn't on the approved list or the patient doesn't meet coverage criteria, the system surfaces the issue before the application — not after the denial.

See how graft tracking works → See compliance guardrails in action →

FAQ

Are all skin substitutes affected by the 2026 changes?

Yes. Every cellular and tissue-based product (CTP) used in wound care is now reimbursed under the new flat-rate structure at ~$127.14/cm². Additionally, roughly 158 products were dropped from Medicare coverage entirely. The impact varies by product — some lower-cost CTPs may still be profitable at the new rate, while premium products that relied on high ASP pricing are significantly affected.

Do I need prior authorization for skin substitutes now?

In some jurisdictions, yes. CMS introduced the WISeR (Wound Integrity and Service Evaluation Report) prior authorization model. Check with your MAC to determine whether prior auth is required in your region. Even where formal prior auth isn't required, the documentation standards for medical necessity have not relaxed.

What if I'm holding graft products that were dropped from coverage?

You have a few options: negotiate returns with your vendor, use the products for non-Medicare patients who can self-pay, or write off the inventory. Do not apply non-covered products to Medicare patients and attempt to bill — this creates audit exposure and potential fraud risk.

How do I know which products are still covered in my MAC jurisdiction?

Check your Medicare Administrative Contractor's website for the current approved product list. CMS also publishes national coverage decisions. Your graft vendor should be able to confirm coverage status, but verify independently — vendor assurances don't protect you in an audit.

The practices that adapt to these changes quickly will gain competitive advantage. The ones that ignore them will face margin erosion, denials, and audit risk. The choice is straightforward — even if the execution isn't easy.

Book a demo to see how Medipyxis protects your practice →